Table 1.
Administration routes of molecular hydrogen in human bodies to combat various infections and/or diseases, along with the respective management strategies.
| Administrative Routes in the Body | Subject/s (Time Taken to Initiate an Action) | Human Body Response/s | Effects on Target Organ or at Injury Site | Administration Protocol | Advantages | Prospective Risks Associated | Ref. |
|---|---|---|---|---|---|---|---|
| Dissolved H2 Saline | Rats (24 h) | Anti-inflammatory and anti-apoptotic effect | Myocardial I/R injury | 10 mL/kg, 0.6 mmol/L, | Direct exposure or inoculation of dose at the target site | Cross-infection, Invasive | [30] |
| Mice (12 h) | Anti-inflammatory response, reduces sepsis associated diseases | Encephalopathy | 5 mL/kg, 0.6 mmol/L | Direct exposure or inoculation of dose at the target site | Cross-infection, Invasive | [31] | |
| Drinking of dissolved H2 water | Human (2 weeks) | Alleviates Injuries | Injured soft tissues (sports-related) | 2 g/day, H2-rich tablets | Safe and portable | Dose intake limitations | [32] |
| Human (4 weeks) | Reduction in inflammation and anti-apoptotic | Peripheral blood vessels and blood cells | 1500 mL/day, 0.753 mg/L | Safe and portable | Dose intake limitations | [33] | |
| Human (8 weeks) | Improves parapsoriasis | Plaques | 10–15 min bathing with H2 water (two times a week) | Safe and portable | Dose intake limitations | [11] | |
| Guinea Pig (10 days) | Immunoregulation and improves allergic rhinitis | Allergic rhinitis | 0.6 mmol/L, 20 μL/day Inoculated through nasal passage |
Safe and portable | Dose intake limitations | [34] | |
| Mice (10 days) | Anti-inflammatory response | EAE 1 symptoms; | 0.89 mM/0.36 Twice/day | Safe and portable | Dose intake limitations | [35] | |
| H2 gas inhalation through nasal routes | Rats (120 min) | Antioxidant, protects from cerebral injury | Cerebral injury (I/R) | 4, 1, or 2% H2 | Dose and intake time can be ensured | If concentration rises above 4%, it may be explosive | [2] |
| Rats (4 months) | Anti-inflammatory, ameliorates COPD | COPD 2 symptoms | 2, 22 or 41.6% H2 For 2 h (Once/day) |
Dose and intake time can be ensured | If concentration rises above 4%, it may be explosive | [36] | |
| Human (7 days) | Anti-inflammatory, ameliorates COPD | COPD symptoms | 6 to 8 h/d, 66.6% H2 | Dose and intake time can be ensured | If concentration rises above 4%, it may be explosive | [37] | |
| Human (daily till discharge) | Ameliorates COVID-19 | COVID-19 | 66.6% H2
33.3% O2 |
Dose and intake time can be ensured | If concentration rises above 4%, it may be explosive | [38] | |
| H2 administration into the body via nanoparticles | Rats (3/24 h) | Antioxidant, anti-inflammatory, ameliorates lung and myocardial injuries | Myocardial injury (I/R), lung injury | 4 × 109 or 2 × 1010 bubbles |
Safe to use, high H2 content/unit volume | Expensive | [10] |
1 EAE: experimental autoimmune encephalomyelitis; 2 COPD: chronic obstructive pulmonary disease.